MetaCap

Pharvaris N.V. (PHVS)

NASDAQ: PHVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

31.28-0.38 (-1.20%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PHVS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.13
52-week range
23.15 – 43.25
Day range
30.43 – 31.99
Volume / Avg
464.00K / 756.20K
Beta
—

52-week range

$23.15$43.25

PHVS stock today

Pharvaris N.V. (PHVS) closed at $31.28 on Nov 20, down 1.20% (-$0.38), versus the S&P 500's 3.70% decline. Shares are 27.7% below their 52-week high of $43.25, set on Sep 8, 2026 and 35.1% above the 52-week low of $23.15, in the middle of the past year's range. PHVS is up 12.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 26.0%.

Pharvaris N.V. has posted a net loss over the last twelve months (EPS of -$3.13), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Pharvaris N.V.

Company profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Headquarters
Zug
Employees
168
IPO year
2021

Financial highlights

Full financials

Pharvaris N.V. reported a net loss of $26.0 million, compared with a loss of $8.0 million a year earlier.

Pharvaris N.V. annual revenue, net income and EPS
Fiscal yearFY 2020FY 2019FY 2018
Revenue———
Growth———
Net income$-25.99M$-8.03M$-4.31M
EPS (diluted)———

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$58.27+86.29%

  • Strong buy 3
  • Buy 11
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $40.19High $78.71

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.77 vs $-0.82
Surprise
+6.10%

PHVS news

All PHVS news

Pharvaris N.V. peers

Health Care sector
PHVS peer companies
CompanyPrice% ChgMarket capCompare
NAMSNewAmsterdam Pharma Company N.V.18.41-5.64%$2.21Bvs PHVS
PRGOPerrigo Company plc15.94-0.62%$2.21Bvs PHVS
LKFTLakefront Biotherapeutics ADR33.31-0.24%$2.18Bvs PHVS
RCUSArcus Biosciences Inc.15.62-1.01%$2.25Bvs PHVS
HCMHUTCHMED (China) Limited ADR13.22-1.71%$2.30Bvs PHVS
PVLAPalvella Therapeutics Inc.142.85-2.00%$2.09Bvs PHVS
PBHPrestige Consumer Healthcare Inc.49.63+0.06%$2.35Bvs PHVS
AUPHAurinia Pharmaceuticals Inc14.70-1.28%$1.97Bvs PHVS

Indexes, lists and sector

Pharvaris N.V. stock FAQ

What is Pharvaris N.V.'s stock price today?

PHVS last traded at $31.28 as of Nov 20, 4:00 PM EST, down 1.20% on the day. Prices are delayed at least 15 minutes.

Who is Pharvaris N.V.'s CEO?

Mr. Berndt Axel Edvard Modig CPA, M.B.A. is the chief executive officer of Pharvaris N.V., which has about 168 employees.

What is the PHVS 52-week high?

The 52-week high for PHVS is $43.25 and the 52-week low is $23.15. The stock is currently 27.7% below its high.

Compare PHVS